Literature DB >> 30393608

Histology versus cytology: PD-L1 testing in non-small cell lung cancer.

Nagio Takigawa1, Nobuaki Ochi1, Hiromichi Yamane1.   

Abstract

Entities:  

Year:  2018        PMID： 30393608      PMCID： PMC6193914          DOI： 10.21037/tlcr.2018.08.08

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  18 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.

Authors:  Eleanor Russell-Goldman; Sasha Kravets; Suzanne E Dahlberg; Lynette M Sholl; Marina Vivero
Journal:  Cancer Cytopathol       Date:  2018-02-05       Impact factor: 5.284

3.  Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.

Authors:  Mari Mino-Kenudson
Journal:  Cancer Cytopathol       Date:  2017-05-04       Impact factor: 5.284

4.  Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx.

Authors:  Birgit G Skov; Torsten Skov
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017-08

5.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

Review 6.  Molecular Pathology of Lung Cancer Cytology Specimens: A Concise Review.

Authors:  Deepali Jain; Sinchita Roy-Chowdhuri
Journal:  Arch Pathol Lab Med       Date:  2018-03-16       Impact factor: 5.534

7.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

8.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

9.  PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?

Authors:  Vanda F Torous; Deepa Rangachari; Benjamin P Gallant; Meghan Shea; Daniel B Costa; Paul A VanderLaan
Journal:  J Am Soc Cytopathol       Date:  2018-02-16

10.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245
View more
  1 in total

Review 1.  Program death ligand-1 immunocytochemistry in lung cancer cytological samples: A systematic review.

Authors:  Swati Satturwar; Ilaria Girolami; Enrico Munari; Francesco Ciompi; Albino Eccher; Liron Pantanowitz
Journal:  Diagn Cytopathol       Date:  2022-03-16       Impact factor: 1.390
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.